Dolby Laboratories (NYSE:DLB) Stock, Quote.Headers.trade-ideas

Dolby Laboratories

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.

DLB Logo

Equities

News

Asset Sales

General

Dolby Laboratories is set to acquire GE Aerospace&#39;s GE Licensing, which holds over 5,000 patents in consumer digital media and electronics. This $429 million acquisition will enhance Dolby&#39;s patent portfolio, strengthening its position in video compression technology. The transaction, expected to close by fiscal year 2024, aims to boost operating margins and EPS in fiscal 2025.

Dolby Laboratories To Acquire GE Licensing In $429M Cash Deal: Strengthens Patent Portfolio

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AAOI

AAPL

AGRI

AMZN

ATUS

BRTX

CCTG

CHTR

CING

CISS

CVKD

DECK

EXPO

FBLG

GSX Techedu Inc. American Depositary Shares

GOTU

ALPS ETF Trusthen & Steers Global Realty Majors ETF

HSAI

Intelligent Bio Solutions Inc. - Common Stock

INBS

KOPN

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

LBRDA

MARK

MCAF

MDVL

MINM

NUZE

PGRU

RCRT

REVB

ROMA

SHOP

TEAM

TRUG

TYRA

Shares of Skechers U.S.A., Inc.  (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results.

Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

AMAT

AMSWA

ATGL

ATKR

BBLG

CHPT

CRIS

CYTO

DOGZ

GDEV

GLOB

IFBD

MANU

MOBV

MOND

MURA

OPTX

QFIN

ROST

SLDB

SNES

TRVG

TWST

VIGL

VNET

WETG

WLGS

ZENV

ZJYL

Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance.

Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Dolby Laboratories Inc

Barrington Research analyst James Goss maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Outperform and maintains $100 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Dolby Laboratories, Maintains $100 Price Target

RIVN

Rivian To Integrate Apple Music's Premium Spatial Audio With Dolby Atmos Support Into All Electric Vehicles For Apple Music Subscribers

WIIM

Dolby Laboratories shares are trading lower after the company cut its Q4 guidance below estimates.

Financial Outlook
Dolby's financial outlook relies, in part, on estimates of royalty-based revenue that take into consideration various factors that are subject to uncertainty, including consumer demand for electronic products. In addition, actual results could differ materially from the estimates Dolby is providing below due in part to uncertainty resulting from the macroeconomic effect of certain conditions, including supply chain constraints, international conflicts, geopolitical instability, and fluctuations in inflation and interest rates. The uncertainty resulting from these factors has greatly reduced its visibility into Dolby's future outlook. To the extent possible, the estimates Dolby is providing for future periods reflect certain assumptions about the potential impact of certain of these items, based upon a consideration of currently available external and internal data and information. These assumptions are subject to risks and uncertainties. For more information, see "Forward-Looking Statements" in this press release for a description of certain risks that Dolby faces, and the section captioned "Risk Factors" in its Quarterly Report on Form 10-Q for the third quarter of fiscal 2024, to be filed on or around the date hereof.
Dolby is providing the following estimates for its fourth quarter of fiscal 2024:
<ul>
<li>Total revenue is estimated to range from $300 million to $320 million.</li>
<li>Licensing revenue is estimated to range from $275 million to $295 million.</li>
<li>Gross margins are anticipated to be approximately 88%.</li>
<li>Operating expenses are anticipated to range from $225 million to $235 million on a GAAP basis and from $190 million to $200 million on a non-GAAP basis.</li>
<li>Effective tax rate is anticipated to be around 29% on a GAAP basis and around 23% on a non-GAAP basis.</li>
<li>Diluted earnings per share is anticipated to range from $0.31 to $0.46 on a GAAP basis and from $0.61 to $0.76 on a non-GAAP basis.</li>
</ul>
Dolby is providing the following estimates for the full year of fiscal 2024:
<ul>
<li>Total revenue is expected to range from $1.27 billion to $1.29 billion.</li>
<li>Gross margins are anticipated to be roughly 89%.</li>
<li>Operating expenses are anticipated to range from $875 million to $885 million on a GAAP basis and from $735 million to $745 million on a non-GAAP basis.</li>
<li>Dolby expects operating margins on a GAAP basis to be roughly 20% and on a non-GAAP basis to be roughly 31%.</li>
<li>Diluted earnings per share is anticipated to range from $2.40 to $2.55 on a GAAP basis and from $3.60 to $3.75 on a non-GAAP basis.</li>
</ul>

Guidance

Dolby Laboratories Sees Q4 EPS $0.61-$0.76 Vs $0.85 Est.; Revenue $300M-$320M Vs $326.6M Est.; FY24 EPS $3.60-$3.75 Vs $3.72 Est.; Revenue $1.27B-$1.29B Vs $1.29B Est.

Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.59 by 20.34 percent. The company reported quarterly sales of $288.818 million which beat the analyst consensus estimate of $286.183 million by 0.92 percent. This is a 3.20 percent decrease over sales of $298.370 million the same period last year.

Earnings

Earnings Beats

Dolby Laboratories Q3 2024 Adj. EPS $0.71 Beats $0.59 Estimate, Sales $288.818M Beat $286.183M Estimate

Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $98.5, a high estimate of $100.00, and a low estimate of $98.00. Observing a 0.51% increase, the current average has risen from the previous average price target of $98.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1717765245_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Dolby Laboratories by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Frankel</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$98.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>James Goss</td>
<td>Barrington Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Frankel</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$98.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Steve Frankel</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$98.00</td>
<td>$98.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dolby Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dolby Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Dolby Laboratories's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Dolby Laboratories's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DLB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dolby Laboratories analyst ratings.</a>
<h2>About Dolby Laboratories</h2>
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
<h3>Understanding the Numbers: Dolby Laboratories's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Dolby Laboratories faced challenges, resulting in a decline of approximately -3.02% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Dolby Laboratories's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 26.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.1%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Dolby Laboratories's ROA stands out, surpassing industry averages. With an impressive ROA of 3.27%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Dolby Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 4 Analyst Ratings Have To Say About Dolby Laboratories

Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and maintains $98 price target.

Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $98 Price Target

Dolby Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>), known for its entertainment services, announced a definitive agreement to acquire GE Aerospace&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) GE Licensing, which specializes in intellectual property licensing in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/n39204581/dolby-laboratories-announces-agreement-to-acquire-ge-licensing-from-ge-aerospace" rel="noreferrer noopener">consumer digital media and electronics sectors.</a>
Dolby Laboratories will acquire GE Licensing in a $429 million all-cash transaction, expected to close by the end of fiscal year 2024.
The deal involves over 5,000 patents, including key patents in video compression technology. This acquisition will bolster Dolby&#8217;s patent portfolio, enhancing its standing in the industry.
GE Aerospace will retain its portfolio of IP related to its core aerospace and defense technologies, as well as the trademark portfolio for the GE brand.
GE Licensing is recognized for its innovations and patents, particularly in video codec technology. Andy Sherman, Dolby&#8217;s Executive Vice President, Patent Licensing and General Counsel, emphasized the strategic importance of this acquisition for Dolby&#8217;s commitment to open standards and collaborative licensing.
Robert Giglietti, CEO of Corporate Holdings and Treasurer at GE Aerospace, stated, &#8220;As GE Aerospace continues to sharpen its focus as a standalone company serving aerospace and defense customers, Dolby is the right partner for ensuring these innovative digital media technologies continue to serve businesses and consumers around the world.&#8221;
The deal, which awaits regulatory approval, will not significantly impact Dolby&#8217;s fiscal 2024 results. Dolby anticipates the acquisition to be accretive to operating margins and EPS on a non-GAAP basis in fiscal 2025.
Dolby held $824.4 million in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38597868/dolby-laboratories-reports-second-quarter-2024-financial-results" rel="noreferrer noopener">cash and equivalents as of March 29, 2024</a>.
The transaction includes complementary assets that enhance Dolby&#8217;s patent portfolios and will not alter Dolby&#8217;s policy of returning capital to shareholders through quarterly dividends and stock repurchases to counterbalance dilution from stock-based compensation.
Price Action: DLB shares are trading higher by 0.14% at $80.07 at the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Acquisition to strengthen Dolby's licensing businesses and create opportunity for future growth
SAN FRANCISCO, June 6, 2024 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>), a leader in immersive entertainment experiences, announced today that it has entered into a definitive agreement to acquire GE Licensing, which owns, maintains, and licenses an extensive portfolio of IP primarily targeting the consumer digital media and electronics sectors.
&nbsp;
Financial Considerations&nbsp;
Dolby Laboratories has agreed to acquire GE Licensing, an intellectual property licensing business primarily targeting the consumer digital media and electronics sectors, in a $429 million all cash transaction. This deal is expected to close by the end of fiscal year 2024, subject to regulatory approval and other customary closing conditions, and is not expected to have a material impact on Dolby's fiscal year 2024 results.&nbsp;This transaction includes attractive complementary assets that strengthen and expand Dolby's patent portfolios, and represents a compelling financial profile of durable, high-margin revenue. Dolby expects the deal to be accretive on a non GAAP basis to operating margins and EPS in fiscal 2025.

Dolby Laboratories To Acquire GE Licensing, An IP Licensing Business Primarily Targeting The Consumer Digital Media And Electronics Sectors, In A $429M All Cash Transaction

Barrington Research analyst James Goss upgrades Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) from Market Perform to Outperform and announces $100 price target.

Upgrades

Barrington Research Upgrades Dolby Laboratories to Outperform, Announces $100 Price Target

With Dolby Atmos across its entire 2024 soundbar lineup, VIZIO and Dolby are leading the way consumers experience astonishing immersive audio
VIZIO (NYSE:<a href="https://www.benzinga.com/stock/VZIO#NYSE">VZIO</a>) and Dolby Laboratories, Inc. (NYSE:<a href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) are teaming up to make Dolby Atmos&#xAE; available to even more consumers, integrating best-in-class immersive sound across VIZIO's entire 2024 soundbar lineup – available now at Best Buy as well as Amazon, Walmart and Sam's Club. As one of the world's first manufacturers to support Dolby Atmos across its full soundbar lineup, VIZIO and Dolby are pioneering multi-dimensional sound experiences to consumers for as low as $99, making it more accessible no matter where they are in their soundbar journey.

VZIO

VIZIO And Dolby Are Teaming Up To Usher In Premium Sound Era For All

Rosenblatt analyst Steve Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and maintains $98 price target.

Dolby Laboratories Continues To See FY24 Total Revenue To Be Roughly $1.30B (Est $1.298B), Adj EPS Of $3.60-$3.75 ($3.69)

Dolby Laboratories Expects Q3 Total Revenue Of $270M-$300M (Est $313.637M), Adj EPS Of $0.51-$0.66 (Est $0.77)

Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.19 by 6.72 percent. This is a 0.79 percent increase over earnings of $1.26 per share from the same period last year. The company reported quarterly sales of $364.523 million which beat the analyst consensus estimate of $359.442 million by 1.41 percent. This is a 3.02 percent decrease over sales of $375.891 million the same period last year.

Dolby Laboratories Q2 2024 Adj EPS $1.27 Beats $1.19 Estimate, Sales $364.523M Beat $359.442M Estimate

Today, February 22, 2024, Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) will distribute a dividend payout of $0.30 per share, highlighting an annualized dividend yield of 1.44%. Shareholders who owned the stock before the ex-dividend date on February 12, 2024 will be eligible for this payout.
<h3>Dolby Laboratories Recent Dividend Payouts</h3>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style><table>
<thead>
<tr>
<th>Ex-Date</th>
<th style="text-align: right;">Payments per year</th>
<th>Dividend</th>
<th>Yield</th>
<th>Announced</th>
<th>Record</th>
<th>Payable</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024-02-12</td>
<td style="text-align: right;">4</td>
<td>$0.3</td>
<td>1.44%</td>
<td>2024-02-01</td>
<td>2024-02-13</td>
<td>2024-02-22</td>
</tr>
<tr>
<td>2023-11-27</td>
<td style="text-align: right;">4</td>
<td>$0.3</td>
<td>1.35%</td>
<td>2023-11-16</td>
<td>2023-11-28</td>
<td>2023-12-05</td>
</tr>
<tr>
<td>2023-08-11</td>
<td style="text-align: right;">4</td>
<td>$0.27</td>
<td>1.23%</td>
<td>2023-08-03</td>
<td>2023-08-14</td>
<td>2023-08-22</td>
</tr>
<tr>
<td>2023-05-15</td>
<td style="text-align: right;">4</td>
<td>$0.27</td>
<td>1.3%</td>
<td>2023-05-04</td>
<td>2023-05-16</td>
<td>2023-05-23</td>
</tr>
<tr>
<td>2023-02-13</td>
<td style="text-align: right;">4</td>
<td>$0.27</td>
<td>1.34%</td>
<td>2023-02-02</td>
<td>2023-02-14</td>
<td>2023-02-22</td>
</tr>
<tr>
<td>2022-11-29</td>
<td style="text-align: right;">4</td>
<td>$0.27</td>
<td>1.54%</td>
<td>2022-11-17</td>
<td>2022-11-30</td>
<td>2022-12-08</td>
</tr>
<tr>
<td>2022-08-22</td>
<td style="text-align: right;">4</td>
<td>$0.25</td>
<td>1.28%</td>
<td>2022-08-09</td>
<td>2022-08-23</td>
<td>2022-08-31</td>
</tr>
<tr>
<td>2022-05-16</td>
<td style="text-align: right;">4</td>
<td>$0.25</td>
<td>1.27%</td>
<td>2022-05-05</td>
<td>2022-05-17</td>
<td>2022-05-25</td>
</tr>
<tr>
<td>2022-02-15</td>
<td style="text-align: right;">4</td>
<td>$0.25</td>
<td>1.14%</td>
<td>2022-02-03</td>
<td>2022-02-16</td>
<td>2022-02-23</td>
</tr>
<tr>
<td>2021-11-29</td>
<td style="text-align: right;">4</td>
<td>$0.25</td>
<td>1.13%</td>
<td>2021-11-16</td>
<td>2021-11-30</td>
<td>2021-12-08</td>
</tr>
<tr>
<td>2021-08-10</td>
<td style="text-align: right;">4</td>
<td>$0.22</td>
<td>0.92%</td>
<td>2021-07-29</td>
<td>2021-08-11</td>
<td>2021-08-19</td>
</tr>
<tr>
<td>2021-05-14</td>
<td style="text-align: right;">4</td>
<td>$0.22</td>
<td>0.85%</td>
<td>2021-05-04</td>
<td>2021-05-17</td>
<td>2021-05-25</td>
</tr>
</tbody>
</table>
When comparing Dolby Laboratories's dividend yield against its industry peers, the company sits comfortably in the middle, with its peer Gen Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) having the highest annualized dividend yield at 2.32%.
<h3>Analyzing Dolby Laboratories Financial Health</h3>
Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. 
<h3>YoY Growth in Dividend Per Share</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1708614319_0.png" alt="dividend chart graph" />
From 2020 to 2023, the company's dividend per share showed a positive trend, increasing steadily from $0.88 in 2020 to $1.11 in 2023. This demonstrates the company's commitment to rewarding shareholders by consistently raising dividends.
<h3>YoY Earnings Growth For Dolby Laboratories</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1708614319_1.png" alt="earning chart graph" />
The earnings chart above shows that from 2020 to 2023, Dolby Laboratories has experienced an increase in their earnings from $2.99 per share to $3.57 per share. This positive earnings trend is promising for income-seeking investors as it suggests that the company has more potential to increase its cash dividend payout if the trend continues.
<h3>Recap</h3>
This article takes an in-depth look at Dolby Laboratories's recent dividend payout and its implications for shareholders. The company is currently distributing a dividend of $0.30 per share today, translating to an annualized dividend yield of 1.44%.
When comparing Dolby Laboratories's dividend yield against its industry peers, the company sits comfortably in the middle, with its peer Gen Digital having the highest annualized dividend yield at 2.32%.
Considering the increase in dividend per share from 2020 to 2023 along with an increase in earnings per share, Dolby Laboratories appears to be in a strong financial position, indicating their ability to sustain dividend distributions to investors.
To stay well-informed about potential changes in financials or dividend disbursements, investors should closely observe the company's performance in the upcoming quarters.
[Click here](<a href="https://www.benzinga.com/stock//dividends" title="https://www.benzinga.com/stock//dividends">https://www.benzinga.com/stock//dividends</a>) to find details on Dolby Laboratories's previous dividends.
To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dividends

Dolby Laboratories Exceeds Expectations with Strong Performance, Driving Profits and Rewarding Investors

Friday marks the last chance for investors to receive the next dividend payout from Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>). 
<h3>What's Happening</h3>
The company announced on Thursday that it would pay shareholders a quarterly dividend of 30 cents per share. On Monday, Dolby Laboratories will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 30 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Monday. Shareholders who own DLB as of the end of Friday's session are eligible to receive the 30 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on February 22, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
To stay up-to-date with the companies that are announcing their dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Dolby Laboratories: Dividend Insights

Shares of Skechers U.S.A., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/skx#NYSE">SKX</a>) shares fell during Friday&rsquo;s session after the company reported mixed fourth-quarter financial results.
Skechers said fourth-quarter revenue increased 4.4% year-over-year to $1.96 billion, which missed the consensus estimate of $2.03 billion, according to Benzinga Pro. The company reported quarterly earnings of 56 cents per share, which beat analyst estimates of 54 cents per share.
Skechers shares fell 6.9% to $59.21 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Intelligent Bio Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) shares jumped 77.6% to $4.28. Intelligent Bio Solutions said it sees preliminary second-quarter revenue of $0.76 million.</li>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) shares rose 34.4% to $6.76 after gaining more than 22% on Thursday.</li>
<li>Remark Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mark#NASDAQ">MARK</a>) shares climbed 33% to $0.6802.</li>
<li>Kopin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kopn#NASDAQ">KOPN</a>) jumped 30% to $2.4050.</li>
<li>BioRestorative Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brtx#NASDAQ">BRTX</a>) rose 26.3% to $2.73.</li>
<li>Mountain Crest Acquisition Corp. IV (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcaf#NASDAQ">MCAF</a>) gained 23% to $14.65.</li>
<li>Tyra Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tyra#NASDAQ">TYRA</a>) gained 21.8% to $15.84. Tyra Biosciences&nbsp;announced a $200 million private placement financing.</li>
<li>Meta Platforms, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) rose 18.9% to $469.34 as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share.</li>
<li>CCSC Technology International Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cctg#NASDAQ">CCTG</a>) gained 18.2% to $4.6099 after dipping around 82% on Thursday.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) gained 15.8% to $0.8697 after gaining around 5% on Thursday.</li>
<li>Deckers Outdoor Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/deck#NYSE">DECK</a>) surged 14% to $879.03 after reporting better-than-expected third-quarter financial results.</li>
<li>Trugolf, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trug#NASDAQ">TRUG</a>) shares jumped 14% to $1.5150 after dipping 55% on Thursday.</li>
<li>Gaotu Techedu Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gotu#NYSE">GOTU</a>) gained 12.5% to $4.11.</li>
<li>PropertyGuru Group Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pgru#NYSE">PGRU</a>) rose 11.6% to $3.57.</li>
<li>NuZee, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuze#NASDAQ">NUZE</a>) gained 11.5% to $1.93.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) shares rose 9.6% to $0.1499. S.H.N. Financial recently reported a 9.1% stake in the company.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aaoi#NASDAQ">AAOI</a>) gained 8.4% to $17.90. Applied Optoelectronics is expected to release financial results for its fourth quarter on Feb. 22, 2024.</li>
<li>Amazon.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) shares rose 6.2% to $169.20 after the company posted stronger-than-expected results for its fourth quarter. The company said it sees first-quarter revenue to be between $138 billion and $143.5 billion versus estimates of $142.13 billion. Operating income is expected to be between $8 billion and $12 billion in the first quarter.</li>
<li>Shopify Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shop#NYSE">SHOP</a>) rose 5.9% to $81.25. Wells Fargo analyst Andrew Bauch maintained Shopify with an Overweight and raised the price target from $70 to $90.</li>
<li>The Clorox Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clx#NYSE">CLX</a>) shares gained 4.6% to $154.77 after the company reported better-than-expected second-quarter financial results and raised FY24 adjusted EPS guidance above estimates.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cingulate Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cing#NASDAQ">CING</a>) shares dipped 48.8% to $1.7206. Cingulate announced pricing of $7.5 million public offering of 3.750 million shares at $2.00 per share.</li>
<li>MedAvail Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdvl#NASDAQ">MDVL</a>) fell 42.5% to $1.8068.</li>
<li>Scienjoy Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sj#NASDAQ">SJ</a>) dipped 37.5% to $2.10.</li>
<li>ADDvantage Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aey#NASDAQ">AEY</a>) fell 23.6% to $0.4659. Addvantage Technologies Group said company and subsidiaries ceased operations on Jan. 26, 2024.</li>
<li>FibroBiologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fblg#NASDAQ">FBLG</a>) fell 23.2% to $13.63.</li>
<li>GRI Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>) fell 21% to $1.54 after the company announced pricing of $5.5 million public offering.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) shares fell 20.7% to $0.3116. AgriFORCE Growing Systems received a Notice of Allowance for U.S. patent application 17/983,109 titled &quot;Automated Growing Systems.&quot;</li>
<li>Cadrenal Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvkd#NASDAQ">CVKD</a>) fell 19.1% to $1.1404.</li>
<li>Recruiter.com Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcrt#NASDAQ">RCRT</a>) declined 19% to $1.15.</li>
<li>Gen Digital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gen#NASDAQ">GEN</a>) fell 17.5% to $19.73 after the company reported worse-than-expected third-quarter financial results and issued FY24 adjusted EPS and FY24 revenue guidance below estimates.</li>
<li>WNS (Holdings) Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wns#NYSE">WNS</a>) dipped 16.7% to $59.99. WNS said one of its top five customers by revenue contribution served termination notice on Jan. 31.</li>
<li>Exponent, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/expo#NASDAQ">EXPO</a>) fell 15.7% to $75.77 following weak earnings.</li>
<li>Hesai Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hsai#NASDAQ">HSAI</a>) fell 14.2% to $3.45.</li>
<li>Liberty Broadband Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lbrda#NASDAQ">LBRDA</a>) dipped 13% to $69.39.</li>
<li>Atlassian Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/team#NASDAQ">TEAM</a>) shares declined 12.8% to $222.08 after the company reported second-quarter financial results.</li>
<li>Charter Communications, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chtr#NASDAQ">CHTR</a>) fell 12.6% to $333.95 following fourth-quarter results. The company missed EPS estimates and reported a loss of 62,000 residential Internet customers.</li>
<li>Kiora Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kprx#NASDAQ">KPRX</a>) shares fell 12.4% to $0.7413. Kiora Pharmaceuticals shares jumped around 54% on Thursday after the company announced a private placement of up to roughly $45 million.</li>
<li>Altice USA, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atus#NYSE">ATUS</a>) fell 8.7% to $2.2620.</li>
<li>Beazer Homes USA, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bzh#NYSE">BZH</a>) declined 7.6% to $29.91 following downbeat earnings.</li>
<li>Revelation Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/revb#NASDAQ">REVB</a>) shares dipped 7.2% to $2.95. Revelation Biosciences shares fell around 64% on Thursday after the company announced the pricing of a $6.2 million offering.</li>
<li>Dolby Laboratories, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dlb#NYSE">DLB</a>) declined 5.2% to $80.42 following quarterly results.</li>
<li>Apple Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) shares fell 1.7% to $183.78. Apple reported better-than-expected earnings and revenue for its first quarter. However, the company reported a revenue decline in China.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/36910509/dow-falls-150-points-us-economy-adds-353-000-jobs-in-january"> Dow Falls 150 Points; US Economy Adds 353,000 Jobs In January</a>

Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Dolby Laboratories, Inc. (DLB) Q3 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Dolby Laboratories (NYSE:<a href="https://investorplace.com/stock-quotes/dlb-stock-quote/">DLB</a>) just reported results for the third quarter of 2024.<ul><li>Dolby Laboratories reported earnings per share of 71 cents. This was above the analyst estimate for EPS of 59 cents.</li><li>The company reported revenue of $288.82 million.</li><li>This was 0.92% better than the analyst estimate for revenue of $286.18 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/dlb-stock-earnings-dolby-laboratories-for-q3-of-2024/">DLB Stock Earnings: Dolby Laboratories Beats EPS, Beats Revenue for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

DLB Stock Earnings: Dolby Laboratories Beats EPS, Beats Revenue for Q3 2024

Dolby Laboratories declares $0.30 dividend

ClearBridge All Cap Growth Strategy Q2 2024 Commentary

Dolby Laboratories (DLB – Research Report), the Industrials sector company, was revisited by a Wall Street analyst today. Analyst James Goss from B...

Dolby Laboratories: A Buy Rating with Growth and Stability Insights

Dividend Champion, Contender, And Challenger Highlights: Week Of August 11

Catalyst Watch: Eyes on Jackson Hole, Target earnings, and Canadian rails disruption

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Dolby Laboratories

Dolby Laboratories (DLB) Forecast

Dolby Laboratories (NYSE:DLB) Stock, Quote.Headers.trade-ideas